Literature DB >> 25569646

Emergency department visits related to cirrhosis: a retrospective study of the nationwide emergency department sample 2006 to 2011.

Chaitanya Pant1, Mojtaba Olyaee, Richard Gilroy, Prashant K Pandya, Jody C Olson, Melissa Oropeza-Vail, Tarun Rai, Abhishek Deshpande.   

Abstract

There is scant literature about cirrhosis and its associated complications in a non-hospitalized population.To study the epidemiology of cirrhosis-associated Emergency Department visits in the US.Estimates were calculated in patients' ≥18 years using the Nationwide Emergency Department Sample.The number of visits associated with an International Classification of Diseases-9 diagnosis code of cirrhosis increased non-significantly from 23.81/10,000 population (2006) to 23.9/10,000 population (2011; P = 0.05). A majority of these patients (75.30%) underwent hospital admission, the greatest risk factor for this was the presence of ≥3 comorbidities (adjusted odds ratio 30.8; 95% Confidence Interval 30.4-31.2). Infection was the most frequent concurrent complicating diagnosis associated with cirrhosis (20.1%). There was a decreased incidence in most of the complicating conditions except for hepatorenal syndrome and spontaneous bacterial peritonitis.Our results indicate a stable trend for cirrhosis-associated Emergency Department visits from 2006 to 2011. Further studies are required to investigate the increased incidence of spontaneous bacterial peritonitis and hepatorenal renal syndrome in the cirrhotic population.

Entities:  

Mesh:

Year:  2015        PMID: 25569646      PMCID: PMC4602843          DOI: 10.1097/MD.0000000000000308

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


INTRODUCTION

Cirrhosis is the eighth leading cause of death in the US and in 2010 accounted for approximately 49,500 deaths, increased from 35,500 deaths in 1990.[1] Patients with cirrhosis carry an increased burden of comorbidities, like depression, drug addiction and coronary artery disease and have cirrhosis-related complications including ascites, hepatorenal syndrome (HRS), esophageal variceal bleeding (EVB), and hepatic encephalopathy (HE).[2] Recent analyses of a national US database indicate a substantial and increasing prevalence of cirrhosis-related complications in hospitalized inpatients.[3-5] However, these results relate to a cohort of cirrhotic patients undergoing inpatient treatment and are not necessarily representative of the disease as it occurs in the outpatient setting. We therefore interrogated a national US Emergency Department (ED) database over a 5-year period from 2006 to 2011 to gain further insight into the epidemiology of cirrhosis and its associated complications in a non-hospitalized population.

MATERIALS AND METHODS

Data Source

We used the Healthcare Cost and Utilization Project Nationwide Emergency Department Sample (HCUP-NEDS) years 2006 to 2011 for our study. The 2011 HCUP-NEDS comprises approximately 29.5 million ED visits sampled from 951 hospitals in 30 US states representing a 20% stratified sample of US hospital-based EDs. Weights are provided to calculate national estimates pertaining to approximately 131 million ED visits in 2011. The NEDS contains event-level records, not patient-level records; individual patients who visit the ED more than once in a year may be recorded in the NEDS multiple times. Each ED visit entry contains 1 primary discharge diagnosis, 1 to 14 secondary diagnoses (based on the International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] diagnosis codes), demographic information, and details of disposition from the ED. Ethical approval was therefore not necessary for the conduct of this study.

Variable Definition

Adult patients were identified starting at age 18 years. We extracted all entries with a primary or secondary discharge diagnosis of cirrhosis (ICD-9-CM codes: 5712, 5715, 5716). Age, sex, insurance status, household income, geographic location of care, and hospital setting were also obtained for the extracted cases. Cases were then queried for complications that are known to occur frequently in patients with cirrhosis. These included infections; urinary tract infection (UTI), skin and subcutaneous tissue infections (SSCI), spontaneous bacterial peritonitis (SBP), Clostridium difficile infection (CDI), or pneumonia were identified using discharge ICD-9-CM codes: UTI (1122, 59010–11, 5902–03, 59080–81, 5950, 5970, 5990); SSCI (680–82, 684, 686); SBP (56723, 5672); CDI (00845), and pneumonia (480–83, 487). Other complications also queried for included HE, HRS, and EVB, which were identified using discharge ICD-9-CM codes: HE (5722), HRS (5724), and EVB (4560, 45620). To assess independent risk factors associated with hospital admission, we assessed and controlled for the presence of comorbidities in our study population. The examined comorbid conditions consisted of 28 disease states contained within the Elixhauser comorbidity index minus the presence of liver disorders.[6] This is a widely used index in which higher scores indicate a greater comorbid disease burden.[7,8]

Statistical Analysis

Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC). The rate of cirrhosis-associated ED visits was expressed per 10,000 census population, thereby adjusting for the increase in the US population over time. Data were obtained from the US Census Bureau, Population Division, Annual Estimates of the Population for the US, Regions, and Divisions and US Census Bureau, Current Population Reports. The Chi-square test was used to compare categorical variables and the 2-proportion Z-test was used to compare rates. Univariate and multiple variable logistic regression models were used to study the association of selected variables of interest with the outcome of admission to the hospital from the ED. For trend analysis, we used the Cochran–Armitage test. The threshold for significance for all analyses was P < 0.01.

RESULTS

During the calendar years 2006 to 2011, there were an estimated total of 3,127,986 ED visits associated with an ICD-9-CM diagnosis code of cirrhosis. Table 1 details the demographic- and hospital-related characteristics of this patient population. The median age of patients was 56 years (interquartile range (IQR) 16) and 61.8% were male compared to 38.20% female patients (P < 0.01). Socioeconomic analyses revealed that 65.20% patients had either Medicare or Medicaid insurance while 31.80% belonged to the lowest national income quartile. The southern region of US accounted for 37.20% of all cirrhosis-associated ED visits. Visits to non-teaching hospitals were more frequent than teaching hospitals (55.70% vs 44.30%; P < 0.01) and most facilities were located in urban areas (84.40%; P < 0.01).
TABLE 1

Demographic- and Hospital-Related Characteristics of Patients Ages 18 Years and Above With a Primary or Secondary Discharge Diagnosis of Cirrhosis Who Visited an Emergency Department (ED) in the US From 2006 to 2011

Demographic- and Hospital-Related Characteristics of Patients Ages 18 Years and Above With a Primary or Secondary Discharge Diagnosis of Cirrhosis Who Visited an Emergency Department (ED) in the US From 2006 to 2011 Regarding the disposition of the patients from the ED, the majority were admitted to the same hospital with a smaller number of routine discharges (75.30% vs 21.10%; P < 0.01). Using multiple variable logistic regression we identified factors that were associated with an increased rate of hospital admission for cirrhosis (Table 2). The greatest risk factors were the presence of ≥3 comorbid conditions (adjusted odds ratio [aOR] 30.8; 95% CI 30.4–31.2), the presence of cirrhosis-associated complications: EVB (aOR 13.9; 95% CI 13.5–14.3), HRS (aOR 5.6; 95% CI 5.4–5.8), HE (aOR 4.4; 95% CI 4.3–4.5), any infection (aOR 3.8; 95% CI 3.7–3.8), and presentation to an ED in the north-east region of the US (aOR 2.3; 95% CI 2.2–2.3).
TABLE 2

Risk Factors Associated With Hospital Admission in Patient With Cirrhosis-Associated Emergency Department (ED) Visits Using a Multiple Variable Regression Model in Patients Ages 18 Years and Above From 2006 to 2011

Risk Factors Associated With Hospital Admission in Patient With Cirrhosis-Associated Emergency Department (ED) Visits Using a Multiple Variable Regression Model in Patients Ages 18 Years and Above From 2006 to 2011 An analysis of temporal trends during the period of our study revealed that cirrhosis-associated ED visits increased slightly from 23.81/10,000 population in 2006 to 23.9/10,000 population in 2011; a non-significant increase of 0.4% (P = 0.05). In a similar period of time for a corresponding age group, the rate of all ED visits increased from 4167.3/10,000 population in 2006 to 4382.5/1000 population in 2011. This represented an increase of 5.2% and indicated an overall increased trend for all ED visits from 2006 to 2011 (P < 0.01). We next determined the co-occurrence of cirrhosis-related complications in our patient population (Table 3). The most frequent category of complicating diagnoses was the presence of any infection (20.1%); UTI was the most common specific infection with an incidence of 10.9%. HE was the next most commonly occurring complication (15.5%) followed by EVB (6.0%) and HRS (4.0%). In the period from 2006 to 2011, there was a decrease in the incidence of both overall and individual complicating infections (P < 0.01) except for SBP, which increased by 14.7% (P < 0.01). Concurrently, there was also a significant decrease in the rates of EVB (23.2%; P < 0.01) and HE (17.7%; P < 0.01), although the rate of HRS did increase by 25.7% (P < 0.01).
TABLE 3

Rates of Cirrhosis-Associated Emergency Department (ED) Visits and Complicating Diagnoses in Patients Ages 18 Years and Above From 2006 to 2011

Rates of Cirrhosis-Associated Emergency Department (ED) Visits and Complicating Diagnoses in Patients Ages 18 Years and Above From 2006 to 2011

DISCUSSION

Our study of the NEDS database demonstrates that the population-adjusted rate of cirrhosis-associated ED visits remained largely stable from 2006 to 2011. Contemporaneously, the population-adjusted rate of all ED visits increased by 5% with an overall increased trend. An examination of the demographic characteristics of the study population highlights a few noteworthy features. First, 37.2% of cirrhosis-associated ED visits were to hospitals in the southern region of the US. Second, 31.8% of the study population belonged to the lowest national income quartile. Last, approximately three-fourths of these patients were admitted to the same hospital, in contrast the admission rate for all ED visits ages 18 and above was approximately 15%. The disparate rate of cirrhosis in the lowest economic strata of society is an area of concern and merits further research relating to potential barriers in accessing treatment by these patients.[4] Infection was overall the most frequent diagnostic category (20.1%) of cirrhosis-associated complications. Patients with cirrhosis are considered to suffer an acquired immunocompromised state and are particularly susceptible to infections, which account for higher mortality, increased renal insufficiency and greater utilization of healthcare resources.[3,9-11] Our results indicate that from 2006 to 2011, the rates of pneumonia, UTI, SSCI, and CDI all decreased significantly; this was particularly evident in the case of pneumonia, which decreased by 33.3%. Interestingly, a recent analysis of the NEDS observed that the national rate of all ED visits due to pneumonia remained stable from 2006 to 2009.[12] There was also a contemporaneous decrease in the rates of HE (17.7%) and EVB (23.2%) during the period of our study. While we can only speculate regarding the causes resulting in these decreased rates; the proliferating role of endoscopic variceal ligation and rifaximin as frontline therapies may have contributed in some measure to this decline. More concerning, is a significant increase in the rate of SBP (14.7%) and HRS (25.7%) in our study population. Unfortunately, the limitations of NEDS preclude further investigation regarding the basis for this escalation. There are several limitations to our study. First, the NEDS contains encounter-level data, therefore, we are unable to assess for hospital readmissions or make patient-level associations across discharges and 1 patient may potentially account for several ED visits. Second, we have relied exclusively on ICD-9-CM codes for case identification. Third, the NEDS has limited clinical and demographic data, which limits our ability to investigate etiology. Fourth, there is a non-availability of data pertaining to Model For End-Stage Liver Disease (MELD) score calculations, medication, and antibiotic usage. Finally, our results represent a weighted estimate of national data. Our analysis of the NEDS indicate a stable incidence of cirrhosis-associated ED visits in the period from 2006 to 2011 with a decreased rate of cirrhosis-related complications except for SBP and HRS. These data represent important complementary information to the study of the overall impact of cirrhosis in the US. Further research should be directed to investigating the increased trends observed for SBP and HRS in the cirrhotic population.
  12 in total

1.  In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009.

Authors:  Maria Stepanova; Alita Mishra; Chapy Venkatesan; Zobair M Younossi
Journal:  Clin Gastroenterol Hepatol       Date:  2012-05-27       Impact factor: 11.382

2.  Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.

Authors:  Vasiliki Arvaniti; Gennaro D'Amico; Giuseppe Fede; Pinelopi Manousou; Emmanuel Tsochatzis; Maria Pleguezuelo; Andrew Kenneth Burroughs
Journal:  Gastroenterology       Date:  2010-06-14       Impact factor: 22.682

Review 3.  Immune dysfunction and infections in patients with cirrhosis.

Authors:  Alexander R Bonnel; Chalermrat Bunchorntavakul; K Rajender Reddy
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-11       Impact factor: 11.382

Review 4.  Bacterial infections, sepsis, and multiorgan failure in cirrhosis.

Authors:  Puneeta Tandon; Guadalupe Garcia-Tsao
Journal:  Semin Liver Dis       Date:  2008-02       Impact factor: 6.115

Review 5.  Comorbidity in cirrhosis.

Authors:  Peter Jepsen
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

6.  Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective.

Authors:  Jasmohan S Bajaj; Ashwin N Ananthakrishnan; Muhammad Hafeezullah; Yelena Zadvornova; Alexis Dye; Emily L McGinley; Kia Saeian; Douglas Heuman; Arun J Sanyal; Raymond G Hoffmann
Journal:  Am J Gastroenterol       Date:  2009-10-20       Impact factor: 10.864

7.  Rates of emergency department visits due to pneumonia in the United States, July 2006-June 2009.

Authors:  Wesley H Self; Carlos G Grijalva; Yuwei Zhu; Candace D McNaughton; Tyler W Barrett; Sean P Collins; Alan B Storrow; Marie R Griffin
Journal:  Acad Emerg Med       Date:  2013-08-27       Impact factor: 3.451

8.  Stroke: the Elixhauser Index for comorbidity adjustment of in-hospital case fatality.

Authors:  Haifeng Zhu; Michael D Hill
Journal:  Neurology       Date:  2008-07-22       Impact factor: 9.910

9.  The state of US health, 1990-2010: burden of diseases, injuries, and risk factors.

Authors:  Christopher J L Murray; Charles Atkinson; Kavi Bhalla; Gretchen Birbeck; Roy Burstein; David Chou; Robert Dellavalle; Goodarz Danaei; Majid Ezzati; A Fahimi; D Flaxman; Sherine Gabriel; Emmanuela Gakidou; Nicholas Kassebaum; Shahab Khatibzadeh; Stephen Lim; Steven E Lipshultz; Stephanie London; Michael F MacIntyre; A H Mokdad; A Moran; Andrew E Moran; Dariush Mozaffarian; Tasha Murphy; Moshen Naghavi; C Pope; Thomas Roberts; Joshua Salomon; David C Schwebel; Saeid Shahraz; David A Sleet; Jerry Abraham; Mohammed K Ali; Charles Atkinson; David H Bartels; Kavi Bhalla; Gretchen Birbeck; Roy Burstein; Honglei Chen; Michael H Criqui; Eric L Ding; E Ray Dorsey; Beth E Ebel; Majid Ezzati; S Flaxman; A D Flaxman; Diego Gonzalez-Medina; Bridget Grant; Holly Hagan; Howard Hoffman; Nicholas Kassebaum; Shahab Khatibzadeh; Janet L Leasher; John Lin; Steven E Lipshultz; Rafael Lozano; Yuan Lu; Leslie Mallinger; Mary M McDermott; Renata Micha; Ted R Miller; A A Mokdad; A H Mokdad; Dariush Mozaffarian; Mohsen Naghavi; K M Venkat Narayan; Saad B Omer; Pamela M Pelizzari; David Phillips; Dharani Ranganathan; Frederick P Rivara; Thomas Roberts; Uchechukwu Sampson; Ella Sanman; Amir Sapkota; David C Schwebel; Saeid Sharaz; Rupak Shivakoti; Gitanjali M Singh; David Singh; Mohammad Tavakkoli; Jeffrey A Towbin; James D Wilkinson; Azadeh Zabetian; Jerry Abraham; Mohammad K Ali; Miriam Alvardo; Charles Atkinson; Larry M Baddour; Emelia J Benjamin; Kavi Bhalla; Gretchen Birbeck; Ian Bolliger; Roy Burstein; Emily Carnahan; David Chou; Sumeet S Chugh; Aaron Cohen; K Ellicott Colson; Leslie T Cooper; William Couser; Michael H Criqui; Kaustubh C Dabhadkar; Robert P Dellavalle; Daniel Dicker; E Ray Dorsey; Herbert Duber; Beth E Ebel; Rebecca E Engell; Majid Ezzati; David T Felson; Mariel M Finucane; Seth Flaxman; A D Flaxman; Thomas Fleming; Mohammad H Forouzanfar; Greg Freedman; Michael K Freeman; Emmanuela Gakidou; Richard F Gillum; Diego Gonzalez-Medina; Richard Gosselin; Hialy R Gutierrez; Holly Hagan; Rasmus Havmoeller; Howard Hoffman; Kathryn H Jacobsen; Spencer L James; Rashmi Jasrasaria; Sudha Jayarman; Nicole Johns; Nicholas Kassebaum; Shahab Khatibzadeh; Qing Lan; Janet L Leasher; Stephen Lim; Steven E Lipshultz; Stephanie London; Rafael Lozano; Yuan Lu; Leslie Mallinger; Michele Meltzer; George A Mensah; Catherine Michaud; Ted R Miller; Charles Mock; Terrie E Moffitt; A A Mokdad; A H Mokdad; A Moran; Mohsen Naghavi; K M Venkat Narayan; Robert G Nelson; Casey Olives; Saad B Omer; Katrina Ortblad; Bart Ostro; Pamela M Pelizzari; David Phillips; Murugesan Raju; Homie Razavi; Beate Ritz; Thomas Roberts; Ralph L Sacco; Joshua Salomon; Uchechukwu Sampson; David C Schwebel; Saeid Shahraz; Kenji Shibuya; Donald Silberberg; Jasvinder A Singh; Kyle Steenland; Jennifer A Taylor; George D Thurston; Monica S Vavilala; Theo Vos; Gregory R Wagner; Martin A Weinstock; Marc G Weisskopf; Sarah Wulf
Journal:  JAMA       Date:  2013-08-14       Impact factor: 56.272

10.  Prevalence and in-hospital mortality trends of infections among patients with cirrhosis: a nationwide study of hospitalised patients in the United States.

Authors:  A K Singal; H Salameh; P S Kamath
Journal:  Aliment Pharmacol Ther       Date:  2014-05-16       Impact factor: 8.171

View more
  10 in total

Review 1.  Bloodstream infections in patients with liver cirrhosis.

Authors:  Michele Bartoletti; Maddalena Giannella; Russell Edward Lewis; Pierluigi Viale
Journal:  Virulence       Date:  2016-02-11       Impact factor: 5.882

Review 2.  Serum interleukin-6 in the diagnosis of bacterial infection in cirrhotic patients: A meta-analysis.

Authors:  Yinlian Wu; Mingfang Wang; Yueyong Zhu; Su Lin
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

3.  "Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics.

Authors:  Carlos G Moscoso; Clifford J Steer
Journal:  Hepat Med       Date:  2019-09-02

4.  Quality improvement initiative increases total paracentesis and early paracentesis rates in hospitalised cirrhotics with ascites.

Authors:  Arun Jesudian; Luis Barraza; Peter Steel; Nicole Shen; Yecheskel Schneider; David Bodnar; Brenna Farmer; Savira Dargar; Cristina Del Toro; Rahul Sharma; Robert S Brown; Jennifer Inhae Lee
Journal:  Frontline Gastroenterol       Date:  2019-04-29

5.  Opportunistic infections in end stage liver disease.

Authors:  Michele Bartoletti; Maddalena Giannella; Sara Tedeschi; Pierluigi Viale
Journal:  Infect Dis Rep       Date:  2018-04-03

6.  Risk factors, mortality and acute kidney injury outcomes in cirrhotic patients in the emergency department.

Authors:  Paulo Ricardo Gessolo Lins; Wallace Stwart Carvalho Padilha; Carolina Frade Magalhaes Giradin Pimentel; Marcelo Costa Batista; Aécio Flávio Teixeira de Gois
Journal:  BMC Nephrol       Date:  2018-10-20       Impact factor: 2.388

Review 7.  Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions.

Authors:  Elda Righi
Journal:  World J Gastroenterol       Date:  2018-10-14       Impact factor: 5.742

8.  Scoring Systems that Predict Mortality at Admission in End-stage Liver Disease.

Authors:  Neeraj Mangla; Ravi Bokarvadia; Mayank Jain; Joy Varghese; Jayanthi Venkataraman
Journal:  Indian J Crit Care Med       Date:  2019-10

9.  Factors Associated with Delayed Paracentesis in Patients with Spontaneous Bacterial Peritonitis.

Authors:  Backer Abdu; Shalaka Akolkar; Christopher Picking; Judith Boura; Marc Piper
Journal:  Dig Dis Sci       Date:  2020-12-03       Impact factor: 3.199

10.  Rifaximin has the potential to prevent complications of cirrhosis.

Authors:  Steven L Flamm; Kevin D Mullen; Zeev Heimanson; Arun J Sanyal
Journal:  Therap Adv Gastroenterol       Date:  2018-09-28       Impact factor: 4.409

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.